Evoworks Bio Awarded Up to $200K in BioTools Innovator VANGUARD Funding
One of only five companies selected for 6-month funded projects advancing life science tools and diagnostics for health security
Evoworks Bio today announced it has been selected for BioTools Innovator VANGUARD Funding, a six-month program powered by BioTools Innovator (BTI) in partnership with the Biomedical Advanced Research and Development Authority (BARDA).* The company is one of only five awardees to receive up to $200,000 in non-dilutive funding to advance a project in the development of EvoNode platform, the world's first elastically scalable vessel for cell culture and protein expression.
Chosen from more than 170 applicants, the VANGUARD awardees represent the most promising innovations in life science tools for bioanalysis, diagnostics, drug discovery, and biomanufacturing that can play a critical role in U.S. health security. Over the 6-month program, participants will work closely with BARDA experts, receive targeted mentorship, and engage with the BioTools Innovator network.
“ We're honored to be selected as a VANGUARD awardee," said Ross Beighley, CEO and Founder of Evoworks Bio. "Too many promising therapies stall between the flask and the bioreactor. This funding lets us close that gap with EvoNode, so teams can move from early discovery to scalable production without losing time or confidence in their data”.
*This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under agreement number 75A50124C00034.
About the VANGUARD Program
BioTools Innovator (BTI) VANGUARD is the Enabling Technologies hub of the Biomedical Advanced Research and Development Authority (BARDA) Accelerator Network as part of BARDA’s ongoing mission to support the development of medical countermeasures to prepare for and respond to dynamic or unpredictable biothreats. VANGUARD is powered by Los Angeles-based BTI, which was established to advance cutting-edge research and improve human health by accelerating the growth of a broad spectrum of life science tools and diagnostics. BTI matches industry leaders with innovative early-stage and emerging growth biotechnology-focused companies for mentorship and support.
About Evoworks Bio
Founded in 2023 and based in Cambridge, MA, Evoworks Bio is a team of technical founders working out of the Engine (Built by MIT) to revolutionize scaling in bioproduction. Our platform, EvoNode, is the world's first elastically scalable vessel for cell culture and protein expression, letting teams move from flasks to larger, clinically relevant volumes without introducing new variables. Our mission is to resolve bioproduction at scale, drastically cutting the cost and time it takes to bring new therapies to market. Evoworks Bio serves diagnostic antibody developers and CDMOs producing complex biologics who need consistent quality and rapid scale-up without compromising speed to market.
View Complete Article: https://www.prnewswire.com/news-releases/evoworks-bio-selected-for-barda-backed-vanguard-program-to-demonstrate-rapid-scalable-production-of-critical-biologics-302832880.html
